SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases

Table 3 The associations of SWI/SNF mutations with TMB and MSI status in different malignancies

Cancer type	Average TMB value (mutations/Mb)			TMB-H proportion			MSI-H proportion
Cancer type	SWI/SNF-non-mutant	SWI/SNF-mutant	p	SWI/SNF-non-mutant	SWI/SNF-mutant	p	SWI/SNF-non-mutant	SWI/SNF-mutant	p
Breast cancer	4.9	9.3	0.001	13.9%	57.1%	0.001	0.0%	0.0%	NA
Cervical cancer	4.7	9.7	0.001	11.7%	40.0%	0.012	1.9%	0.0%	0.999
Colorectal cancer	7.2	44.1	< 0.0001	1.6%	39.6%	< 0.0001	1.2%	33.2%	< 0.0001
Endometrial cancer	6.2	61.6	< 0.0001	14.3%	75.8%	< 0.0001	8.9%	48.5%	< 0.0001
Esophagus cancer	6.5	13.9	< 0.0001	24.1%	75.0%	0.013	0.0%	0.0%	NA
Gallbladder and Biliary tract cancer	6.1	17.6	0.019	16.7%	43.5%	0.063	3.3%	17.4%	0.154
Gastric cancer	4.2	15.3	0.002	7.2%	31.6%	< 0.0001	0.0%	12.3%	0.0004
Kidney cancer	3.5	9.1	0.004	7.4%	28.6%	0.180	0.0%	0.0%	NA
Liver cancer	4.6	12.4	0.003	11.6%	33.3%	0.050	0.0%	6.7%	0.179
Melanoma	3.3	6.8	< 0.0001	3.8%	20.0%	0.042	0.0%	0.0%	NA
Non-small cell lung cancer	5.6	12.7	< 0.0001	18.9%	53.0%	< 0.0001	0.2%	1.1%	0.086
Other	4.0	16.6	< 0.0001	9.1%	51.1%	< 0.0001	1.0%	2.2%	0.462
Ovarian and Fallopian tube cancer	3.7	9.1	< 0.0001	3.6%	18.4%	< 0.0001	1.1%	4.6%	0.059
Pancreatic cancer	4.0	6.7	0.006	3.9%	12.5%	0.203	1.3%	0.0%	0.999
Prostatic cancer	6.9	46.1	0.010	12.5%	33.3%	0.422	6.3%	33.3%	0.298
Small cell lung cancer	9.2	22.1	0.016	58.8%	100.0%	0.521	0.0%	0.0%	NA
Soft tissue sarcoma	2.5	9.4	< 0.0001	4.4%	42.9%	0.0002	2.7%	14.3%	0.093
Urothelial cancer	7.3	15.1	0.005	32.6%	57.9%	0.092	0.0%	5.3%	0.306
Total	5.6	25.8	< 0.0001	44.3%	10.3%	< 0.0001	0.9%	16.0%	< 0.0001

Mb megabase, MSI-H high microsatellite instability, SWI/SNF switch/sucrose nonfermentable, TMB-H high tumor mutation burden

ISSN: 1475-2867